Placebo-adjusted mean weight loss of 11.3% (27.3 lbs) with 120 mg dose in the 36-week Phase 2b ACCESS study with a 10.4% adverse event-related treatment discontinuation Placebo-adjusted mean weight ...
SAN FRANCISCO, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for ...
SAN FRANCISCO, Dec. 07, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic ...
PORTSMOUTH, N.H.--(BUSINESS WIRE)-- Albany International Corp. (NYSE: AIN) announced today that it is exploring strategic alternatives for its structures assembly business, including a potential sale ...
Albany International Initiates Review of Strategic Alternatives for Structures Assembly Business; Announces Loss Reserve Adjustment for CH-53K Program; Schedules Earnings Release Date Third-Quarter ...
We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up for any (or all) of our 25+ Newsletters. Some states have laws and ethical rules regarding solicitation and ...
Programming Aptamer–Protein Complexation Kinetics via Modulation of G-Quadruplex Secondary Structure
Department of Biomedical Engineering, McCormick School of Engineering, Northwestern University, Evanston, Illinois 60208, United States Department of Chemistry, University of Kansas, Lawrence, Kansas ...
Chip programming solutions provider Data I/O was recently targeted in a ransomware attack that has caused significant disruption to the company’s operations. Data I/O offers electronic device ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback